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OBJECTIVES The purpose of this study was to test the hypothesis that polymorphisms in the promoter
region of the glutamate-cysteine ligase catalytic subunit (GCLC) gene may be associated with
coronary endothelial vasomotor dysfunction and myocardial infarction (MI).
BACKGROUND Glutamate-cysteine ligase is a rate-limiting enzyme for synthesis of glutathione (GSH) that
plays a crucial role in the intracellular antioxidant defense systems. Oxidants transcriptionally
upregulate the GCLC gene for GSH synthesis, providing a protective mechanism against
oxidant-induced endothelial dysfunction or activation, which plays a pathogenetic role in
cardiovascular diseases.
METHODS The association of the possible polymorphisms with coronary arterial diameter responses to
acetylcholine was determined in 62 male subjects. The frequency of polymorphisms was
compared between 255 male patients with MI and 179 male control subjects.
RESULTS We found a polymorphism (129C/T) in which the T allele showed lower promoter activity
(50% to 60% of the activity of the C allele) in response to H2O2 in human endothelial cells.
Endothelium-dependent dilation of coronary arteries was impaired in subjects with the
129T allele (n 31), as compared with the age-matched subjects without the129T allele
(n  31). The T allele was highly frequent in patients with MI as compared with control
subjects, and it was a significant risk factor for MI, independent of traditional coronary risk
factors (odds ratio [OR] 1.81, 95% confidence interval [CI] 1.08 to 3.03; p  0.03).
CONCLUSIONS The 129T polymorphism of the GCLC gene may suppress the GCLC gene induction
response to an oxidant, and it is implicated in coronary endothelial vasomotor dysfunction and
MI. (J Am Coll Cardiol 2003;41:539–45) © 2003 by the American College of Cardiology
Foundation
BASIC SCIENCE IN CONTEXT
There are many factors that determine a person’s risk for the development of
atherosclerosis, including dyslipidemia, diabetes, hypertension, inflamma-
tion, and oxidative stress. Recently, considerable attention has been given to
the prospect that natural genetic variability in genes, known as single
nucleotide polymorphisms (SNPs, pronounced “snips”), may identify genetic
risk factors for coronary artery disease that are related to known risk factors.
The SNPs are common, small genetic variations that can occur within a
person’s deoxyribonucleic acid sequence.
The current study identifies a novel SNP in the promoter region of the
glutamate-cysteine ligase catalytic subunit gene (GCLC), a gene that has an
important role in the synthesis of other genes that prevent damage from
oxidative stress. In addition to identifying the SNP, the study shows that the
SNP is more frequently present in patients with myocardial infarction, and
that it is associated with increased coronary artery endothelial dysfunction.
Importantly, the report also demonstrates that the SNP in the promoter
region of the gene has a functional effect on the activity of the promoter. All
of these combined increase the likelihood that the SNP described in this report
is a risk factor for myocardial infarction.
—Kirk Knowlton
University of California at San Diego
La Jolla, California
Endothelial dysfunction or activation is known to be an
early event in atherosclerotic development and importantly
contributes to the pathogenesis of coronary artery disease
(1–3). Coronary risk factors alter endothelial functions,
partially through oxidative stress as a common feature of the
risk factors (1–7). We have shown that oxidative stress plays
a crucial role in the pathogenesis of endothelial vasomotor
dysfunction in patients with coronary risk factors, including
hypercholesterolemia (1), smoking (4), diabetes (5), and
hypertriglyceridemia (6,7).
There are various antioxidant defense systems against
oxidative stress in mammalian cells. Exposure to oxidants
may initiate an adaptive intracellular antioxidant response
(i.e., induction of antioxidant genes such as manganese
superoxide dismutase) (8), thioredoxin reductase (9), metal-
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lothionein (10), and glutathione (GSH) (11,12), protecting
cells from subsequent exposure to oxidant stresses. Gluta-
thione, a triple peptide present in virtually all cells, has a
predominant role in the regulation of the intracellular redox
state and protects cells from oxidative injury (12). Indeed,
GSH depletion has been demonstrated to suppress endo-
thelial nitric oxide production (13). Furthermore, we and
others have shown that GSH supplementation improved an
endothelial vasomotor abnormality in the coronary arteries
of patients with coronary risk factors or coronary spastic
angina in which oxidative stress has a pathogenic role
(14–16). Glutathione is synthesized within the cells by the
action of glutamate-cysteine ligase (GCL) (12,17).
Glutamate-cysteine ligase is a heterodimer composed of a
heavy catalytic subunit (GCLC) and a light regulatory
subunit (GCLR) (12,17). The GCLC gene has catalytic
activity and works in the physiologic concentrations of
glutamine under GCLR (12,17). It has been shown that
GSH production is paralleled with GCLC gene expression,
which is regulated primarily at the transcription level
(11,17–19). The GCLC gene is shown to have oxidative
stress-responsive elements in the promoter/enhancer region
(11,17–19). Several cis-acting deoxyribonucleic acid (DNA)
elements contribute to the transcriptional upregulation of
the GCLC gene in response to oxidative stress, providing a
protective mechanism against oxidative stress (11,17,18).
A weakness in the defense system of vascular cells against
oxidative stress, as well as an increase in oxidative stress,
might potentially contribute to endothelial vasomotor dys-
function. A genetic weakness in the antioxidant defense
system might have an influence on the disease susceptibility
of vascular cells to coronary risk factors, as there is a
considerable variation in the vasomotor response of coro-
nary arteries among patients with the same risk factor
profiles. Thus, this study examined the hypothesis that the
functional variations in the promoter region of the GCLC
gene may be present, and that they may be implicated in the
endothelial vasomotor dysfunction of coronary arteries.
Furthermore, we examined the possible association of gene
variants with myocardial infarction (MI) in which oxidative
stress-induced endothelial dysfunction may play a pathoge-
netic role (20).
METHODS
Study subjects enrolled for analysis of the association of
GCLC gene polymorphism with coronary vasomotor
function. This study initially enrolled 179 consecutive male
subjects (mean age 59 years [range 23 to 81 years]) who had
quantitative coronary angiography with an intracoronary
injection of acetylcholine (ACh) (4) at Kumamoto Univer-
sity Hospital. All of them underwent diagnostic cardiac
catheterization for evaluation of atypical chest pain or
ST-segment depression on rest or exercise electrocardio-
grams, without chest pain. It is well known that the
coronary endothelial vasomotor response to ACh is consid-
erably affected by coronary risk factors, especially age (21).
To reduce this influence, we compared coronary vasomotor
functions between all subjects with the minor allele at the
polymorphic sites and age-matched subjects without the
minor allele from the initially enrolled 179 subjects. Age
matching was performed by a computer-based method to
exclude a selection bias. All of the 179 subjects also served
as control subjects for the analysis of polymorphisms with
MI, and their characteristics are shown in Table 1. All of
the 179 subjects had angiographically normal coronary
arteries (10% narrowing after nitrate administration) and
no coronary spasm during intracoronary infusion of ACh
(4). No subject had a previous MI, congestive heart failure,
cardiomyopathy, valvular heart disease, left ventricular hy-
pertrophy, or other serious diseases. All medications were
withdrawn at least three days before the study. None of the
study subjects had taken pharmacologic doses of antioxi-
dants for at least one month before the study. Written,
informed consent for this study and genetic analysis was
obtained from all subjects before the study. The study
protocol was in agreement with the national guidelines for
the genetic analysis in Japan and was approved by the ethics
committee at Kumamoto University Hospital.
Quantitative coronary angiography. A quantitative coro-
nary angiographic study was performed in all of the 179
subjects in the same manner, as described in previous reports
(4,6,14,15). In brief, after baseline angiography, ACh (50
g/min) was infused directly into the left coronary artery
through the Judkins catheter for 2 min, and then angiog-
raphy was performed. After an additional 15 min, an
Abbreviations and Acronyms
ACh  acetylcholine
bp  basepair
DNA  deoxyribonucleic acid
GCL  glutamate-cysteine ligase
GCLC  glutamate-cysteine ligase-catalytic subunit
GCLR  glutamate-cysteine ligase-regulatory subunit
GSH  reduced glutathione
HUVECs  human umbilical vein endothelial cells
MI  myocardial infarction
PBS  phosphate-buffered saline
PCR  polymerase chain reaction
Table 1. Clinical Characteristics of Control Subjects and
Patients With MI for Analysis of the Association Between
GCLC Gene Polymorphism and MI
Control
Subjects
(n  179)
Patients
With MI
(n  255)
p
Value
Age (yrs) 59  13 67  11  0.001
Hypertension 70 (39.1%) 138 (54.1%)  0.001
Diabetes mellitus 41 (22.9%) 87 (34.1%)  0.01
Total cholesterol (mg/dl) 187  33 195  40  0.05
Cigarette smoking 119 (66.5%) 146 (57.3%) 0.91
Body mass index (kg/m2) 23.9  3.4 23.7  3.3 0.62
Data are presented as the mean value  SD or number (%) of patients.
GCLC glutamate-cysteine ligase-catalytic subunit; MImyocardial infarction.
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intracoronary injection of isosorbide dinitrate (1 mg) was
given. Two minutes after that, coronary angiography was
performed in multiple projections in all study subjects. The
trunk of the left anterior descending coronary artery was
divided into proximal and distal segments of equal length.
The lumen diameter at the center of each segment was
measured quantitatively with the use of a computer-assisted
coronary angiographic analysis system (Cardio 500, Kon-
tron Instruments, Mu¨nchen, Germany) by two observers
(H. F. and O. H.) who were blinded to the clinical data of
the study subjects. Coronary artery diameter responses to
infusion of ACh and nitrate were expressed as percent
changes from baseline coronary diameters.
Patients and control subjects for analysis of the associa-
tion of GCLC gene polymorphism with MI. This study
also included 255 consecutive male patients with MI who
underwent coronary angiography at Kumamoto University
Hospital. These patients were examined for a possible
association of GCLC gene polymorphisms with MI. The
clinical characteristics of these patients with MI are shown
in Table 1. Criteria for MI included chest symptoms,
characteristic electrocardiographic changes, and elevation of
creatine kinase to more than twice the upper limit of
normal. The findings of coronary angiography and left
ventriculography supported the diagnosis of MI. Written,
informed consent for the genetic analysis was obtained from
all patients before the study. The study protocol was also
approved by the ethics committee at Kumamoto University
Hospital.
All of the 179 consecutive men who were initially
enrolled for analysis of the association of GCLC gene
polymorphism with coronary vasomotor function served as
control subjects for analysis of the association of GCLC gene
polymorphism with MI.
Identification of polymorphisms in the promoter re-
gion. Genomic DNA was extracted from peripheral blood
lymphocytes by using the phenol chloroform protocol. The
promoter region of the GCLC gene was amplified by
polymerase chain reaction (PCR) from genomic DNA
obtained from 12 patients with MI and 12 control subjects,
using 11 sets of primer pairs covering the region from
3753 to 520, on the basis of the published sequence of
the GCLC promoter sequence (18). The PCR products
were sequenced by using the ABI PRISM dye terminator
cycle-sequencing kit (Perkin-Elmer, Norwalk, Connecticut)
on an ABI Genetic Analyzer 373S (PE Biosystem, Foster
City, California). Sequences were analyzed and compared
among the patients and control subjects to detect polymor-
phisms.
Genotyping. We identified two polymorphisms that were
not linked: 3506A/G and 129C/T. Genotypes of each
polymorphism were determined by the PCR-based restric-
tion fragment length polymorphism method by two inves-
tigators (S. S. and S. K.) who had no knowledge of the
angiographic and clinical data of the control subjects and
patients. The 129C/T polymorphism creates another
novel site for the Tsp45I restriction enzyme in the presence
of the T allele. A set of primers was designed to amplify a
613-base pair (bp) fragment of the GCLC promoter by PCR
(forward: 5-TCGTCCCAAGTCTCACAGTC-3; re-
verse: 5-CGCCCTCCCCGCTGCTCCTC-3 (Hok-
kaido System Science, Sapporo, Japan), encompassing the
129C/T polymorphic site and an additional site for
Tsp45I as a control. Subjects with the CC genotype were
identified by the presence of 500- and 113-bp bands; those
with the TT genotype were identified by the presence of
302-, 198-, and 113-bp bands; and those with the CT
genotype were identified by the presence of all four bands, as
shown in Figure 1.
Similarly, the 3506A/G polymorphism creates another
novel site for the NlaIII restriction enzyme in the presence
of the G allele. A set of primers was designed to amplify an
874-bp fragment of the GCLC promoter by PCR (forward:
5-AAGTCCCAGGAAGAATCACA-3; reverse: 5-
CGCTCTCCAGGAACCCATCT-3 (Hokkaido System
Science), encompassing the 3506A/G polymorphic site
and an additional site for NlaIII as a control. Subjects with
the AA genotype were identified by the presence of 722-,
104-, and 48-bp bands; those with the GG genotype were
identified by the presence of 513-, 209-, 104-, and 48-bp
bands; and those with the AG genotype were identified by
the presence of all five bands.
Cell culture. Primary cultures of human umbilical vein
endothelial cells (HUVECs) were obtained as previously
described (22). The HUVECs at second passage were used
in this study.
Construction of GCLC reporter vectors containing the
129C/Tpolymorphic site. Recombinant expression vec-
tors were created by cloning restriction fragments isolated
from the 5-flanking sequences of the GCLC gene into
pGL3-Basic (Promega, Madison, Wisconsin) for determi-
nation of promoter activity. Two DNA fragments covering
Figure 1. Ethidium bromide gel showing three genotypes from a single
nucleotide polymorphism (C or T) in the promoter region 129 bases
upstream of the GCLC gene. The 613-bp polymerase chain reaction
amplification fragment contains an invariant Tsp45I restriction site, yield-
ing a constant 113-bp fragment seen in all lanes. Individuals homozygous
for the C allele have no additional Tsp45I restriction sites and consequently
show only two bands: at 500-bp and the invariant band at 113-bp. The
129T allele creates an additional Tsp45I site such that homozygous
T-allele individuals have three bands at 302-, 198-, and 113-bp. Heterozy-
gous individuals show all four bands.
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the region from 1393 to 493 were amplified by PCR
with genomic DNA (from 129C wild-type homozygote
or129T variant homozygote) and sequenced. The fragments
were isolated by Xho I/Hind III restriction digestion and
cloned into the Xho I/Hind III sites of pGL3-Basic, creating
the recombinant plasmid pGL3-GCLCwildtype; 129C and
pGL3-GCLCvariant; 129T, respectively.
Luciferase reporter gene assay. The DNA was introduced
into the cells by the liposome-mediated transfection
method. Briefly, subconfluent cultures of HUVECs in a
six-well tissue culture plate were transfected using LIPO-
FECTIN Reagent (Life Technologies, Inc., Rockville,
Maryland). The transfection used 1 g of pGL3 luciferase
reporter vector with the GCLC promoters and 0.025 g of
PRL-TK control vector (Promega), with the herpes simplex
virus thymidine kinase promoter to provide constitutive
expression of Renilla luciferase expression in 2 ml of
serum-free medium per one well. Forty-eight hours after
transfection, the transfected cells were treated for 18 h with
100 mol/l of H2O2 or phosphate-buffered saline (PBS) as
a time control. The treated cells were harvested using
passive lysis buffer (Promega). Luciferase activity was mea-
sured using a dual-luciferase assay system (Promega) and
luminometer. Luciferase levels were expressed in arbitrary
units after normalization to Renilla luciferase levels.
Nuclear extracts preparation and electrophoretic mobil-
ity shift assay. Confluent HUVECs were treated with 100
mol/l of H2O2 or PBS in serum-free medium for 1 to
18 h. After the treatment, nuclear extraction from the cells
and electrophoretic mobility shift assay were performed as
described previously (22). The sequences of the probes
containing the 129C/T polymorphic site were as follows:
GCLCwildtype; 129C: 5-GCTCCCCTCAACTGCGAC-
CCAATCACCCTT-3; GCLCvariant; 129T: 5-GCTC-
CCCTCAACTGTGACCCAATCACCCTT-3 (Hok-
kaido System Science).
Statistical analysis. Mean values of continuous variables
with normal distribution and frequencies between groups
were compared by the unpaired t test and chi-square
analysis or the Fisher exact test, respectively. To evaluate the
129T polymorphism as an independent risk factor differ-
ing between patients with MI and control subjects, multiple
logistic regression analysis was performed using the follow-
ing factors as categorical co-variates: age (70 years),
smoking history (defined as smoking 10 cigarettes per day
for 10 years), hypertension (140/90 mm Hg or current
treatment with antihypertensive medication), diabetes mel-
litus (according to the American Diabetes Association
report [23]), hypercholesterolemia (220 mg/dl), body
mass index (26 kg/m2), and the 129T polymorphism
(TT and CT genotypes). Statistical significance was defined
as p 0.05. Analyses were performed partly using StatView
version 5.0 (SAS Institute, Cary, North Carolina).
RESULTS
Identification of GCLC gene polymorphisms and associ-
ation with MI. Two novel polymorphisms (129C/T and
3506A/G) were identified in the 5-flanking region of the
GCLC gene. The two polymorphisms were not linked.
Figure 1 shows representative agarose gels loaded with PCR
products encompassing the 129C/T polymorphic site
after digestion with Tsp45I.
The 129TT, CT, and CC genotypes were present in 8
(3.1%), 64 (25.1%), and 183 (71.8%) of the 255 consecutive
male patients with MI, respectively, and they were present
in 1 (0.5%), 30 (16.8%), and 148 (82.7%) of the 179 male
control subjects, respectively. The genotype distribution in
either patients with MI or control subjects was consistent
with the population being in Hardy-Weinberg equilibrium.
In analyses of the additive and dominant effects of the
129T polymorphism, the frequencies were significantly
higher in patients with MI than in control subjects (p 
0.01), as shown in Table 2. The129T polymorphism (TT
and CT genotypes) was a significant risk for MI, indepen-
dent of the traditional coronary risk factors in multivariate
logistic regression analysis (odds ratio [OR] 1.81, 95%
confidence interval [CI] 1.08 to 3.03; p  0.03).
The frequency of the 3506A/G polymorphism was
comparable between patients with MI and control subjects
(data not shown).
Effects of GCLC gene polymorphisms on coronary vaso-
motor responses. The frequencies of coronary risk factors
were comparable between subjects with and without the
129T allele, as shown in Table 3. Intracoronary ACh
infusion dilated 13 proximal and 15 distal coronary seg-
Table 2. Genotype Frequencies of GCLC 129C/T Polymorphism in Control Subjects and
Patients With MI
Control Subjects
(n  179)
Patients With MI
(n  255)
OR
(95% CI) p Value
129C/T
GCLC/TT 1/179 (0.5%) 8/255 (3.1%) — —
GCLC/CT 30/179 (16.8%) 64/255 (25.1%) — —
GCLC/CC 148/179 (82.7%) 183/255 (71.8%) — —
129T allele vs. C allele — — 1.90 (1.23–2.92)  0.005
129TT and CT vs. CC — — 1.88 (1.17–3.02)  0.01
129TT vs. CT and CC — — 5.77 (0.72–46.53) 0.059*
*Fisher’s exact probability test. Data are presented as the number (%) of patients.
CI  confidence interval; GCLC  glutamate-cysteine ligase-catalytic subunit; MI  myocardial infarction; OR  odds ratio.
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ments and constricted the remaining segments (18 proximal
and 16 distal segments), resulting in a dilator response of
both coronary segments, as a whole, in the 129CC
subjects (Fig. 2). In contrast, the ACh infusion dilated six
proximal and five distal coronary segments and constricted
the remaining segments (25 proximal and 26 distal seg-
ments), resulting in a constrictor response of both coronary
segments, as a whole, in the129CT and TT subjects (Fig.
2). Nitrate dilated coronary arteries with a comparable
magnitude between subjects with and without the T allele
(percent diameter change from baseline in proximal seg-
ment: 24  1% in the 129CC subjects vs. 24  2% in the
129CT and TT subjects, p  NS; distal segment: 24 
2% in the 129CC subjects vs. 25  2% in the 129CT
and TT subjects, p  NS). The 3506A/G polymorphism
did not affect the coronary vasomotor response to either
ACh or nitrate (data not shown).
Promoter activities of the GCLC gene. We examined the
effects of only the 129C/T polymorphism on the pro-
moter activities because this polymorphism, but not the
3506A/G, was associated with coronary vasomotor dys-
function and MI. The luciferase activity in cells transfected
with the construct containing the 129T allele was signif-
icantly lower than that in cells with the 129C allele in the
control condition (PBS), as shown in Figure 3. The lucif-
erase levels were induced in either cells with the 129T or
129C allele when cells were treated with H2O2, but the
induced levels were significantly lower in cells with the
129T allele than in those with the129C allele, as shown
in Figure 3.
Electrophoretic mobility shift assay. A nuclear protein
complex with the sequence of GCLC gene promoter con-
taining the 129C allele was observed in the control
condition (PBS), as shown in Figure 4. The nuclear protein
complex with the 129C probe was induced earlier when
cells were treated with H2O2. However, the specific com-
plex with the sequence containing the 129T allele was
very weakly observed in either the control condition (PBS)
or with H2O2 treatment, as shown in Figure 4.
DISCUSSION
Association of 129C/T polymorphism of the GCLC
gene with coronary vasomotor dysfunction. The present
study identified two polymorphisms in the promoter region
of the GCLC gene: 129C/T and 3506A/G. The asso-
ciation study showed that subjects with 129C/T and T/T
genotypes are highly associated with abnormal vasomotor
reactivity in epicardial coronary arteries, as reflected by
enhanced constriction or impaired dilation in response to
ACh, whereas the 3506A/G polymorphism was not
associated. The epicardial coronary dilator response to
nitrate, an endothelium-independent dilator, was not sig-
nificantly different between the 129C/C genotype and
C/T and T/T genotypes. Thus, endothelial vasomotor
function of coronary arteries is impaired in subjects with the
129T allele.
Glutathione is synthesized from its constituent amino
acids in two sequentials by GCL and GSH synthetase (12).
Glutamylcysteine, synthesized by GCL, is rapidly converted
to GSH by GSH synthetase. Glutamate-cysteine ligase is
the rate-limiting enzyme in GSH synthesis, whereas GSH
Table 3. Clinical Characteristics of Study Subjects for Analysis
of the Association Between 129C/T Polymorphism and
Coronary Vasomotor Function
129CC
Genotype
(n  31)
129CT or
TT Genotype
(n  31) p Value
Age (yrs) 61  10 61  10 NS
Diabetes mellitus 11 (35.5%) 7 (22.6%) NS
Cigarette smoking 25 (80.6%) 24 (77.4%) NS
Hypertension 11 (35.5%) 10 (32.3%) NS
Total cholesterol (mg/dl) 182  27 195  29 NS
Body mass index (kg/m2) 23.7  2.4 24.1  3.3 NS
Data are presented as the mean value  SD or number (%) of patients.
MI  myocardial infarction; NS  not significant.
Figure 2. Percent changes (mean  SEM) in lumen diameter from
baseline in response to acetylcholine in the proximal and distal segments of
the left anterior descending coronary arteries in subjects with the129C/T
or T/T genotype (solid bars) (n  31) and in age-matched subjects with
the 129C/C genotype (open bars) (n  31).
Figure 3. Effects of the 129C/T polymorphism on GCLC promoter
activity in human umbilical vein endothelial cells. The transfected cells
were incubated for 18 h with H2O2 (100 mol/l) or phosphate-buffered
saline (PBS) (as a time control). Promoter activity is expressed as relative
luciferase activity normalized to Renilla activity. Data are presented as the
mean value  SEM from eight independent experiments. *p  0.05, †p 
0.01. Open bars  129C; solid bars  129T.
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synthetase had apparently no regulatory role (12,17). When
cells are challenged with sublethal oxidative stress or GSH
depletion, GCLC gene expression was upregulated through
activation of oxidative stress-responsive elements in the
promoter regions (11,17–19). This leads to GSH synthesis
and provides a protective/adaptive mechanism against oxi-
dative stress (11,12). In this context, the present study
demonstrated that the 129T allele had lower promoter
activity either in the control condition or after H2O2
treatment. Thus, the 129T polymorphism may suppress
the increase in GCLC gene expression in response to
oxidative stress, and it may possibly weaken the intracellular
production of GSH in response to oxidative stress, leading
to an increase in the susceptibility to oxidant-induced
endothelial injury, which is thought to occur as a part of the
pathogenesis of coronary vasomotor abnormality. Further-
more, the present gel-shift assay showed that the exposure
of human endothelial cells to H2O2 increased the binding of
one nuclear protein factor to the oligonucleotide probe
around the 129 position with the C allele, whereas the
same band was very weakly observed with the T allele probe.
Thus, the nuclear protein bound more strongly to the
sequence with the C allele may be an activator of transcrip-
tional activity. Although there is no putative enhancer
element that contains the 129 position on the computer-
based data research, there are several binding sites for
nuclear proteins (i.e., CCAAT binding protein, near the
129C/T polymorphic site). Thus, it is possible that the
129T allele might modify the binding of nuclear proteins
to unidentified cis-elements around the 129 position,
leading to suppression of GCLC gene expression.
Association of 129C/Tpolymorphism of GCLC gene
with MI. Oxidative stress upregulates endothelial expres-
sion of pro-atherothrombogenic molecules and causes en-
dothelial vasomotor dysfunction in coronary arteries, lead-
ing to coronary events (1–7). Also, GSH suppresses the
induction of these molecules and improves abnormal endo-
thelial vasomotor function (7,14,15). The present study also
showed that the 129T allele is highly frequent in patients
with MI. Although this association was only marginal and
based on a small population size, the present results indicate
that the 129T allele may increase the susceptibility of
oxidative stress-induced endothelial dysfunction or activa-
tion, leading to atherothrombotic events in patients with
MI.
Previous reports. Evidence suggests that low levels of
serum GSH are a risk of coronary artery disease (24).
Administration of buthionine sulfoximine, an inhibitor of
GCL activity, for several weeks severely suppressed both
basal and inducible GSH production to 20% of normal
GSH levels in animal models, resulting in cell damage in
the kidney, lung, and brain (25). It has been previously
reported that a genetic defect in GCLC is associated with a
severe decrease in the intracellular GSH content and causes
hemolytic anemia and neurologic and psychiatric disorders
(26,27). However, there was no description regarding car-
diovascular disorders in these previous reports, probably
because intracellular GSH levels were undetectable or ex-
tremely low, leading to severe cell damage in major organs,
such as the liver, kidney, or brain, where GSH has a crucial
role in their functions rather than cardiovascular systems.
Therefore, the animals treated with buthionine sulfoximine
and the patients with a GCLC complete defect may not
serve as a model of MI, which develops over an extremely
long-term process and occurs in older age in subjects with
the present polymorphism in GCLC gene.
Study limitations. This study is limited by the relatively
small number of control subjects and patients studied. It is
hard to demonstrate direct evidence that intracellular GSH
levels in coronary vascular cells are decreased in subjects
with the 129T allele. Furthermore, the mechanisms by
which the 129T polymorphism in the GCLC gene is
Figure 4. Electrophoretic mobility shift assay: allele-specific binding of nuclear protein to the 129C/T polymorphic site. Nuclear extracts were obtained
from human umbilical vein endothelial cells after treatment for the indicated time with H2O2 (100 mol/l) or phosphate-buffered saline (PBS) (as a time
control). Left panel  interaction with the 129C probe; right panel  interaction with the 129T probe.
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linked to pathogenesis of coronary endothelial vasomotor
dysfunction and MI remain undefined. We cannot exclude
the possibility that this polymorphism is a marker for other
functional gene variants. Also, a case-control study has a
cross-sectional nature, and it may have an inherent selection
bias of cases and controls. A longitudinal study with a large
number of study patients with homogeneous risk is required
to assess the precise role of this gene variant in the
pathogenesis of cardiovascular diseases.
Conclusions. The 129T polymorphism of the GCLC
gene may suppress GCLC gene induction, and it is impli-
cated in coronary endothelial vasomotor dysfunction and
MI.
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